Simon Bossart

Dr. Simon Bossart

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2022 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
SBSimon Bossart
Simon Bossart
CDCloé Daneluzzi
Cloé Daneluzzi
SCSimone Cazzaniga
Simone Cazzaniga
ARAlbert‐Adrien Ramelet
Albert‐Adrien Ramelet
HUHeiko Uthoff
Heiko Uthoff
TWTorsten Willenberg
Torsten Willenberg

12 March 2020 in Acta Dermato-Venereologica
Verified
Journal Article
Open access
SBSimon Bossart
Simon Bossart
VIV Imstepf
V Imstepf
RHRobert Emil Hunger
Robert Emil Hunger
SJS. Morteza Seyed Jafari
S. Morteza Seyed Jafari
Is missing (Short communication)...

4 June 2020 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
SBSimon Bossart
Simon Bossart
MGMax Philip Gabutti
Max Philip Gabutti
SJS. Morteza Seyed Jafari
S. Morteza Seyed Jafari
RHRobert E. Hunger
Robert E. Hunger

15 September 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
SBSimon Bossart
Simon Bossart
CDCloé Daneluzzi
Cloé Daneluzzi
MMMatthias B. Moor
Matthias B. Moor
CHCédric Hirzel
Cédric Hirzel
KHKristine Heidemeyer
Kristine Heidemeyer
DSDaniel Sidler
Daniel Sidler
CSCC (cutaneous squamous cell carcinoma) and its precursors are a major cause of morbidity, especially in immunosuppressed patients, and are frequently associated with human papillomavirus (HPV) infections. The purpose of this study is to investigate the therapeutic potential of alpha-HPV vaccination for immunosuppressed patients with established cSCC and its precursors. In this retrospective study, all patients who received Gardasil-9®, a nonavalent HPV vaccine, as secondary prophylaxis were examined. Dermatologic interventions in both the pre- and post-vaccination periods were analyzed with zero-inflated Poisson regression and a proportional intensity model for repeated events with consideration of the clinically relevant cofactors. The hazard ratio for major dermatologic interventions was 0.27 (CI 0.14–0.51, p < 0.001) between pre- and post-Gardasil-9® intervention. Gardasil-9® vaccination showed good efficacy in reducing major dermatologic interventions even after correction of relevant cofactors and national COVID-19 caseloads during the observational period. Alpha-HPV vaccination may potentially cause a significant decrease in dermatologic interventions and overall mortality as well as healthcare costs in immunosuppressed patients with high skin tumor burden.

13 August 2022 in Bioengineering
Verified
Journal Article
Open access
PDF file
MBMichael Benzaquen
Michael Benzaquen
MMMohammad Munshi
Mohammad Munshi
SBSimon Bossart
Simon Bossart
LFLaurence Feldmeyer
Laurence Feldmeyer
VEVladimir Emelianov
Vladimir Emelianov
KHKristine Heidemeyer
Kristine Heidemeyer
Dose spacing (DS) can be useful for optimizing treatment with biologics in psoriasis patients. However, interval prolongation might increase the production of anti-drug antibodies (ADA) and, therefore, reduce the drug’s effectiveness. The long-term effects of DS with adalimumab in psoriatic patients have not been reported. The goal of our study was to evaluate the long-term follow-up of psoriatic patients after adalimumab DS regarding the clinical course and determination of circulating adalimumab, TNFα levels, and anti-adalimumab antibodies. We retrospectively included seven patients treated with adalimumab for moderate-to-severe psoriasis and benefiting from DS from 2010 to 2021. The dose interval of adalimumab was extended to three weeks for all patients and then to four weeks for three of the seven patients. Adalimumab trough levels, TNFα levels, and ADA against adalimumab were measured. For six of the seven patients, absolute PASI values remained below 3 throughout the follow-up period (median = 8.0 years; range: 1.7–11.5) after DS. All the patients were satisfied with the effectiveness of their treatment regime. Within the follow-up period, an average of 63 doses of adalimumab per patient were spared. The median adalimumab trough levels were 4.7 µg/mL (range: 1.9–12.5). TNFα levels remained under 10 pg/mL (undetectable) in all except one patient. ADA against adalimumab remained negative (<10 µg/mL) during the follow-up in all patients. Our data indicate that therapeutic drug monitoring, including the measurement of trough concentrations and ADA, together with the clinical response and patient’s preference, can be helpful for clinical decision making and treatment optimization in psoriasis.

1 May 2020 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
SBSimon Bossart
Simon Bossart
KMKonrad Mühlethaler
Konrad Mühlethaler
CGChristian Garzoni
Christian Garzoni
HFHansjakob Furrer
Hansjakob Furrer
Objectives: In this study, we compared IFA and real-time PCR in bronchoalveolar lavage specimens of HIV infected patients. A total of 66 BALs from 62 HIV patients were included in the study. 30 IFA positive and 36 IFA negative specimens were tested with real-time PCR, targeting the major surface glycoprotein. We performed a retrospective analysis of the patient’s medical records, compared the results of the IFA and PCR tests and analyzed costs, expenditure of time and personal expenses. Results: All of the 30 IFA positive samples were PCR positive. 35 of 36 IFA negative probes were also negative in the PCR assay. Considering the PCR results as a binary outcome (positive/negative) sensitivity was 100%, specificity 97.2%. The patient with negative IFA and positive PCR had a clear clinical picture of PCP and responded to PCP treatment. PCR was more than twice as expensive and time-consuming as IFA. Diagnostic accuracy for PCP of PCR and IFA was comparable in HIV-infected patients, but IFA was significantly less expensive and less time-consuming. Therefore, IFA testing can continue to be used as gold standard in the diagnosis of PCP in HIV patients. However, in special cases, IFA may lack sensitivity and PCR should be added to the diagnostic armamentarium.